Study identifies potential gain of function mutation in retinoblastoma

A new research paper was published in Volume 16 of Genes & Cancer on January 20, 2025, entitled, “Analysis of pathogenic variants in retinoblastoma reveals a potential gain of function mutation.”

Alcon touts PhIII win for dry eye drug, plans mid-2024 FDA filing

Alcon is looking to file its top clinical candidate for FDA approval mid-year after clinching positive Phase III results. Its eye drop candidate, AR-15512, helped

January 11, 2024

The next act for a biotech rainmaker

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian

February 29, 2024

Psyence Appoints Intellectual Property Expert to Its Board of Directors – Psychedelic Alpha

TORONTO, July 11, 2023 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce the appointment

July 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.